Annual report pursuant to Section 13 and 15(d)

OTHER RELATED PARTY TRANSACTIONS (Details Narrative)

v3.22.2
OTHER RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Jun. 17, 2021
Jun. 15, 2021
Mar. 09, 2021
May 31, 2021
Mar. 31, 2021
Apr. 30, 2022
Related Party Transaction [Line Items]            
[custom:ConsultingExpenses]           $ 383,000
William Horne [Member]            
Related Party Transaction [Line Items]            
Number of shares issued for services, value       $ 50,000    
IPO [Member] | Mr Ault [Member]            
Related Party Transaction [Line Items]            
Description of conversion       the effectiveness of the IPO, and in consideration for (i) the conversion of 750,000 shares of the Company’s Series A Preferred Shares beneficially owned by Mr. Ault through Ault Life Sciences, Inc. into 15,000,000 shares of common stock; (ii) the extension of the maturity date of the note in the original principal amount of $15,000,000 issued to the Company by ALSF, an entity controlled by Mr. Ault, to December 31, 2023; and (iii) the resignation by Mr. Ault as a director and executive officer of the Company    
Percentage of outstanding common shares       5.00%    
D P L [Member]            
Related Party Transaction [Line Items]            
[custom:ConsultingExpenses]           $ 88,000
Securities Purchase Agreement [Member] | Digital Power Lending [Member]            
Related Party Transaction [Line Items]            
Number of shares sold (in shares) 2,000,000 2,000,000     6,666,667  
Number of shares sold $ 10,000,000.0       $ 10,000,000  
Description of related party transaction     DPL paid $4 million, less the $1.8 million in prior advances and the surrender for cancellation of a $50,000 convertible promissory note held by BitNile, for an aggregate of 2,666,667 shares of common stock. Under the terms of the SPA, DPL (i) purchased an additional 1,333,333 shares of common stock upon approval of the IND for Phase I clinical trials for AL001 for a purchase price of $2 million; and (ii) purchased 2,666,667 shares of common stock upon the completion of the Phase I clinical trials for AL001 for a purchase price of $4 million      
Description of milestones         In addition, the Company issued DPL warrants to purchase an aggregate of 6,666,667 shares of common stock at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of eighteen (18) months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of the date of this Annual Report  
Share price (in dollar per shares) $ 5.00 $ 5.00        
Consulting Agreement [Member] | IPO [Member] | Mr Ault [Member]            
Related Party Transaction [Line Items]            
Advisory and consulting services fees       $ 50,000